Skip to main content

Key Product Details

Species Reactivity

Human

Applications

CyTOF-ready, Intracellular Staining by Flow Cytometry

Label

Janelia Fluor 585

Antibody Source

Monoclonal Mouse IgG2B Clone # 462902

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Product Specifications

Immunogen

E. coli-derived recombinant human FRS2
Asn121-Asn449
Accession # Q8WU20

Specificity

Detects human FRS2 in direct ELISAs.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG2B

Applications for FRS2 Antibody (462902) [Janelia Fluor® 585]

Application
Recommended Usage

CyTOF-ready

Optimal dilutions of this antibody should be experimentally determined.

Intracellular Staining by Flow Cytometry

Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Protein A or G purified

Formulation

50mM Sodium Borate

Preservative

0.05% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C in the dark.

Background: FRS2

FGFs (Fibroblast Growth Factors) bind to FGF receptors (FGFRs) monovalently, and FGF receptor dimerization and activation is mediated by multivalent interactions between heparin sulfate proteoglycans and FGF. Upon activation, receptor tyrosine kinases undergo rapid autophosphorylation on numerous tyrosine residues. Autophosphorylation sites located within the catalytic domain are crucial for stimulation of kinase activity, while autophosphorylation sites located in other regions are usually involved in the recruitment of cellular target proteins. Fibroblast growth factor or nerve growth factor (NGF) stimulation leads to tyrosine phosphorylation of the FGF Receptor Substrate 2 (FRS2) docking proteins. FRS2 is also designated SNT (Suc-1 associated neurotrophic factor target protein). Two structurally similar forms of FRS2 are: FRS2a (SNT-1) and FRS-2b (SNT-2, FRS3). FRS functions as a lipid-anchored docking protein that is tyrosine phosphorylated and recruited to FGFR upon FGF stimulation. FRS2 plays an important role in linking FGF and NGF with the Ras/MAPK signaling pathway, thus relaying information from the cell surface to the nucleus. FRS2 contains both a consensus myristylation sequence, involved in its recruitment to the cell membrane and a putative phosphotyrosine binding (PTB)domain in its amino-terminus. The interaction of FRS2 with FGFR1 occurs via the PTB domain of FRS2 binding to a 12-residue segment in the juxtamembrane region of FGFR1. FRS2a contains four binding sites for the adaptor protein Grb2 and two binding sites for the protein tyrosine phosphatase Shp2. FGF stimulation leads to phosphorylation of Shp2 on a tyrosine residue forming a complex with an additional molecule of Grb2. Grb2/Sos complexes are thus recruited directly and indirectly via Shp2 upon tyrosine phosphorylation of FRS2a in response to growth factor stimulation. It has been shown that FRS2 proteins are tyrosine phos phorylated in response to activation of the RET receptor, a tyrosine kinase that functions as the signal transducing receptor for the GDNF.

Long Name

Fibroblast Growth Factor Receptor Substrate 2

Alternate Names

FRS2alpha, SNT1

Gene Symbol

FRS2

Additional FRS2 Products

Product Documents for FRS2 Antibody (462902) [Janelia Fluor® 585]

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for FRS2 Antibody (462902) [Janelia Fluor® 585]



Sold under license from the Howard Hughes Medical Institute, Janelia Research Campus.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...
Loading...
Loading...